News | Pharmaceuticals | November 15, 2018

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes

Fewer MACE events observed with Farxiga vs. placebo in DECLARE-TIMI 58 Trial, but finding did not reach statistical significance

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes

November 15, 2018 — AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) as a late-breaking abstract at the American Heart Association (AHA) Scientific Sessions 2018, Nov. 10-12 in Chicago. Results were simultaneously published in the New England Journal of Medicine (NEJM).1

DECLARE-TIMI 58 is the largest SGLT-2 inhibitor (SGLT-2i) CVOT conducted to date, including more than 17,000 patients across 33 countries. Results showed that Farxiga significantly reduced the risk of hospitalization for heart failure (hHF) or CV death composite vs. placebo by 17 percent (4.9 percent vs. 5.8 percent; HR 0.83 [95 percent CI 0.73-0.95], p=0.005), one of the two primary efficacy endpoints. The reduction in hHF or CV death was consistent across the entire patient population, which included those with CV risk factors and those with established CV disease.1 Farxiga is not indicated to reduce the risk of CV events or hHF.

Additionally, there were fewer major adverse cardiovascular events (MACE) observed with Farxiga for the other primary efficacy endpoint, however this did not reach statistical significance (8.8 percent for Farxiga vs. 9.4 percent for placebo; HR 0.93 [95 percent CI 0.84-1.03], p=0.17).1

DECLARE-TIMI 58 also confirmed the safety profile for Farxiga, which met the primary safety endpoint of non-inferiority vs. placebo, demonstrating no increase in the composite of MACE, defined as CV death, heart attack or stroke.1

On other relevant safety measures, the trial showed no imbalance with Farxiga vs. placebo in amputations (1.4 percent vs. 1.3 percent), fractures (5.3 percent vs. 5.1 percent), bladder cancer (0.3 percent vs. 0.5 percent) or Fournier’s gangrene (1 case vs. 5 cases). The respective incidences of diabetic ketoacidosis (0.3 percent vs. 0.1 percent) and genital infections (0.9 percent vs. 0.1 percent) were rare.1

Although secondary endpoints were only nominally significant, the renal composite endpoint showed that Farxiga reduced the rate of new or worsening nephropathy by 24 percent vs. placebo across the broad patient population studied (4.3 percent vs. 5.6 percent; HR 0.76 [95 percent CI 0.67-0.87]), and there were fewer all-cause mortality events with Farxiga vs. placebo (6.2 percent vs. 6.6 percent; HR 0.93 [95 percent CI 0.82-1.04]).1

Farxiga is not indicated to reduce the risk of HF, other CV outcomes, nephropathy or all-cause mortality.

FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations — October 2019 update

For more information: www.nejm.org

 

Reference

1. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, Nov. 10, 2018. DOI: 10.1056/NEJMoa1812389

Related Content

cardiac arrest cath lab
News | AHA | November 21, 2019
November 21, 2019 — People who experience cardiac arr...
heart disease
News | AHA | November 20, 2019
November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without
 Assorted pastries
News | AHA | November 20, 2019
November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories,
marijuana leaf
News | AHA | November 20, 2019
November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of...
In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff 

Feature | AHA | November 19, 2019
November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of C
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor
Here is a list of the key late-breaking clinical study presentations at the 2019 American Heart Association (AHA)...
 doctor heart failure patient from CorAssist
News | AHA | November 14, 2019
November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering f
 e-cigarette Image by Lindsay Fox from Pixabay

 Image courtesy Lindsay Fox from Pixabay

News | AHA | November 14, 2019
November 14, 2019 — A new study from researchers at the Sm...
 Cholesterol test prep blood draw needle stick from American Heart Association
News | AHA | November 14, 2019
November 14, 2019 — A large majority of patients with atherosclerotic cardiovascular disease (ASCVD) in the...
Overlay Init